Form 8-K - Current report:
SEC Accession No. 0001140361-24-037173
Filing Date
2024-08-14
Accepted
2024-08-14 07:00:24
Documents
14
Period of Report
2024-08-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20034097_8k.htm   iXBRL 8-K 37347
2 EXHIBIT 10.1 ef20034097_ex10-1.htm EX-10.1 534390
  Complete submission text file 0001140361-24-037173.txt   833144

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA atai-20240814.xsd EX-101.SCH 3856
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE atai-20240814_lab.xml EX-101.LAB 22690
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atai-20240814_pre.xml EX-101.PRE 16546
17 EXTRACTED XBRL INSTANCE DOCUMENT ef20034097_8k_htm.xml XML 4210
Mailing Address 524 BROADWAY NEW YORK NY 10013
Business Address WALLSTRASSE 16 BERLIN 2M 10179 (617)-699-5876
ATAI Life Sciences N.V. (Filer) CIK: 0001840904 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40493 | Film No.: 241204068
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)